The Deal
Sunday, November 8, 
7:54 am

Still holding on...

  Share     E-Mail    Discussion    Print Story

Johnson & Johnson just can’t let Guidant go.

The New Brunswick, N.J.-based healthcare titan improved upon its $21.5 billion bid – which it originally lowered from $25.4 billion, but has now upped to $23.2 billion – for the Indianapolis heart device maker yesterday, which the Guidant board approved.

The greater offer price was in response to a bid by Boston Scientific Corp., J&J’s Natick, Mass.-based rival to take Guidant for $25 billion. The company was slated to approve toe offer yesterday, before J&J coughed up the additional chunk of change. Boston Scientific, however, has vowed to continue to fight for the company, hurt last year by product recalls and dips in revenue, which originally agreed to go to J&J in December 2004.

Stay tuned as the drama unfolds. — Carolyn Murphy

Johnson & Johnson raises Guidant bid
Boston formalizes Guidant bid 
Today's Deals

Continue reading below

Also on Dealscape





Post a comment





The Deal Pipeline

Deal Video


Inside The Deal: Linklaters' Schmidt says how regulators handled Pfizer Inc.'s acquisition of Wyeth is an outlier of how others merger reviews will be conducted.


More video...

Crisis On Wall Street
Technology
Deals of The Decade

Community

Industry Insight

Dealing with frozen bank lending

If your bank is not willing to lend, what can you do as your company continues to seek growth?


Judgment Call

The coming age of the renminbi

The Chinese currency will play an increasingly important role in international commerce and finance.


Industry Insight

Banking on PE investments

Howls of protest greeted the FDIC policy statement, but the financial services industry should get over it.


footspacer.jpg footspacer.jpg footspacer.jpg footspacer.jpg footspacer.jpg


©Copyright 2009, The Deal, LLC. All rights reserved. Please send all technical questions, comments or concerns to the Webmaster.